NCCN 2021 Virtual Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™

October 8, 2021

The management of cancer is constantly evolving through the introduction of new advances related to cancer treatment and supportive care. This program will provide hematology/oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Information is focused on current and critical issues to provide hematology/oncology nurses with practical information that can be implemented in the practice setting.

Target Audience

This program is designed to meet the educational needs of hematology/oncology nurses and nurse practitioners who manage patients with hematologic malignancies.

Learning Objectives

The goal of this activity is to ensure that hematology/oncology nurses, as members of the interprofessional oncology care team, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with hematologic malignancies. Following this program, participants should be able to:

  • Evaluate advances in the management of patients with hematologic malignancies and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care.
  • Review issues related to: using technology to facilitate education for patients receiving transplantation; financial toxicity in the care of patients with hematologic malignancies; decreasing emergency department visits in patients who have received chemotherapy; treatment considerations for older patients with AML; and new treatment options in multiple myeloma.

Session Learning Objectives

Using Technology to Facilitate Education for Patients Receiving Transplantation

  • Discuss the advantages and challenges of adapting transplant educational content to a virtual platform.
  • Identify key principles used to optimize the patient and caregiver experience with no in-person contact.
  • Analyze virtual transplant educational programs for best practices that may be applied post-pandemic.

Financial Toxicity in the Care of Patients with Hematologic Malignancies

  • Review prevalence, risk factors, and consequences related to financial toxicity in patients treated for hematologic malignancies.
  • Identify financial implications of new therapies approved to treat hematologic malignancies.
  • Discuss techniques to reduce financial toxicity for patients.

Decreasing Emergency Department Visits in Patients Who Have Received Chemotherapy

  • Discuss CMS measures regarding ED visits in patients who have recently had chemotherapy and the ramifications on quality of care, cost, and patient satisfaction.
  • Describe tools and resources that could be used for standardized educational pathways to help patients with side effect management.
  • Review how data may be collected and shared to help decrease ED visits and demonstrate the impact nursing can have on this important measure.

Treatment Considerations for Older Patients with Acute Myeloid Leukemia

  • List the factors to be considered when choosing the most appropriate treatment options for older adult patients.
  • Provide examples of indications for the use of hematopoietic cell transplantation.
  • Describe the management strategies for toxicities associated with the treatment of AML in older adult patients.

New Treatment Options in Multiple Myeloma

  • Describe indications for treatment of smoldering myeloma.
  • Provide examples of new treatment options, toxicity profiles, and management in multiple myeloma.
  • Discuss the role of minimum residual disease (MRD) in the monitoring of multiple myeloma.
Additional information

This activity is supported by educational grants from:

  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Pfizer Inc.

This educational activity is supported by an educational grant from GlaxoSmithKline.

This educational activity is supported by a medical education grant from Karyopharm® Therapeutics.

Course summary
Available credit: 
  • 3.75 ANCC contact hours
  • 3.75 Participation
Course opens: 
Course expires: 
Event starts: 
10/08/2021 - 10:30am EDT
Event ends: 
10/08/2021 - 3:30pm EDT

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, 
re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Janet Bagley, MS, RN, AOCNS
Penny Moore, DNP, RN, OCN, NEA-BC
Jennifer Peterson, MSN, RN, OCN, BMTCN

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Yi Lisa Hwa, APRN, CNP, DNP
Akcea Therapeutics, Inc.: Honoraria 
sanofi-aventis U.S.: Honoraria

Glen J. Peterson, RN, DNP, ACNP
AbbVie, Inc.: Product/Speakers’ Bureau

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this educational activity for a maximum of 3.75 contact hours.

Available Credit

  • 3.75 ANCC contact hours
  • 3.75 Participation


Please login or register to take this course.

Click the Take Course button to start the credit claiming process.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for certificate viewing/printing